Pre-clinical safety evaluation of pyrrolidine dithiocarbamate.
Basic Clin Pharmacol Toxicol
; 107(3): 758-67, 2010 Sep.
Article
en En
| MEDLINE
| ID: mdl-20406205
ABSTRACT
Pyrrolidine dithiocarbamate (PDTC) was examined for its potential in the intranasal treatment of human rhinovirus infections. Prior to clinical testing, a comprehensive non-clinical programme was performed to evaluate the general toxicity of PDTC. The animal experiments included investigations in rodents with study durations ranging from single dose to repeated dosing over a period of 28 days. The routes of administration were intranasal, inhalative, oral and intravenous for single-dose toxicity and pharmacokinetic studies, and intranasal for repeated dose studies. Blood and tissue samples were obtained from PDTC-treated rats to analyse pharmacokinetics and tissue distribution. Accumulation of selected metals due to PDTC treatment was examined in liver, brain, nerves and fat tissues.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Antivirales
/
Pirrolidinas
/
Tiocarbamatos
Límite:
Animals
/
Female
/
Humans
/
Male
Idioma:
En
Año:
2010
Tipo del documento:
Article